.tb-container[data-toolset-blocks-container="8c13577c35fd68d7b70a2a5270dfdf0d"] { border-radius: 10px;padding: 25px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-container[data-toolset-blocks-container="93f4094e2a5fc591c3cbd3f80a56f302"] { border-radius: 10px;padding: 25px;box-shadow: 5px 5px 10px 1px rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] { text-align: center; } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px -5px rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__content { text-shadow: 5px 5px 10px rgba( 0, 0, 0, 0.5 );color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__icon { font-family: dashicons;margin-right: 10px; } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__icon::before { content: '\f103'; } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-fields-and-text[data-toolset-blocks-fields-and-text="d8ee833869d806ba93519c93a0c99d68"] { border-top: 1px dotted rgba( 0, 0, 0, 1 );border-right: 0px dashed rgba( 0, 0, 0, 1 );border-bottom: 0px dashed rgba( 0, 0, 0, 1 );border-left: 0px dashed rgba( 0, 0, 0, 1 ); } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] { text-align: center; } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__content { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__icon { font-family: dashicons; } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] { text-align: center; } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__content { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__icon { font-family: dashicons; } @media only screen and (max-width: 781px) { .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; }  } @media only screen and (max-width: 599px) { .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; }  } 
Báo cáo thường niên năm 2019 của Five Prime Therapeutics Inc
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND stage for pigmented villonodular synovitis and multiple cancers in combination with nivolumab.
Báo cáo thường niên của Five Below Inc năm 2019